Varian has received FDA 510(k) clearance for its Varian Proton Therapy System, which generates protons for precision radiotherapy of lesions, tumors and conditions where radiation treatment is indicated.
The system delivers intensity modulated proton therapy (IMPT) using pencil beam scanning technology, which provides options for delivering dose to spare healthy tissue during treatment delivery, stated Palo Alto, Calif.-based Varian.
Proton therapy destroys tumors by delivering protons that stop at specified depths within the anatomy. Varian said its scanning beam technology enables IMPT by modulating dose levels on a spot-by-spot basis throughout the treatment area. The company said that scanning beam IMPT technology eliminates the need to manually insert separate shaping accessories for each beam angle to match the beam to the shape of the tumor.
Varian is actively marketing its system under the ProBeam brand, and it has been selected as the preferred supplier for several proton therapy projects, including the Scripps Proton Therapy Center under construction in San Diego where treatments are scheduled to begin in 2013, according to Varian. The company's scanning beam IMPT technology is already at work in the Rinecker Proton Therapy Center in Germany, which has now treated several hundred patients.
Varian manufactures medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy.